Expert Interview
Discussing the potential of Merck's V116 pneumococcal vaccine candidate along with the clinical data from the STRIDE phase 3 trials reviewing V116 for the prevention of invasive pneumococcal disease
Ticker(s): MRK- Treats 500 patients with a smoking addiction
- Very Familiar with the development of AXS-05
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
